Mochida Pharmaceutical Ends Pain Killer License Deal With Wyeth
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Mochida Pharmaceutical announced April 13 it has ended a license agreement with Wyeth on a TRPV1 antagonist for pain relief